

UNITED STATES PATENT AND TRADEMARK OFFICE

AF/ IFW
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/883,550	06/18/2001	William E. Marshall	P01936USS	1897
22885	7590	08/22/2008	EXAMINER	
MCKEE, VOORHEES & SEASE, P.L.C. 801 GRAND AVENUE SUITE 3200 DES MOINES, IA 50309-2721			ZEMAN, ROBERT A	
		ART UNIT	PAPER NUMBER	
		1645		
		MAIL DATE	DELIVERY MODE	
		08/22/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	09/883,550	MARSHALL, WILLIAM E.
	Examiner	Art Unit
	ROBERT A. ZEMAN	1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 02 November 2007 and 07 May 2008.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1,4-8, 10-12 and 14-19 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1,4-8, 10-12 and 14-19 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>11-2-2007</u> . | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The amendment filed on 5-7-2008 is acknowledged. Claims 1 and 6-7 have been amended. Claims 1, 4-8, 10-12 and 14-19 are pending and currently under examination.

Information Disclosure Statement

The Information Disclosure Statement filed on 11-2-2007 has been considered. An initialed copy is attached hereto.

Claim Objections Withdrawn

The objection to claim 6 for failing to italicize genus names is withdrawn in light of the amendment thereto.

The objection to claim 7 for failing to define abbreviations upon their first recitation is withdrawn in light of the amendment thereto.

Claim Rejections Maintained

35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 4-6, 8, 10-12 and 14-19 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for methods for modulating the immune system of an animal comprising exposing bacterial to two or more sequential periods of stress;

separating said bacteria from the medium; filtering clarified medium to remove all substances with a molecular weight greater than 10kDa; and administering the filtrate to said animal wherein the bacteria is *L. caseii*, *L. acidophilus*, *L. fermentum*, *L. plantarum*, *L. monocytogenes*, *S. aureus*, *S. typhimurium*, *P. acidolactici*, *B. coryneforme*, *E. coli*, *E. faecium*, *S. pyogenes* or *K. pneumoniae*, does not reasonably provide enablement for said method of modulating the immune system of an animal utilizing any other species of bacteria. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make/use the invention commensurate in scope with these claims.

Applicant argues:

1. The test for enablement is not merely quantitative, since a considerable amount of experimentation is possible, if it is merely routine.
2. Claims may encompass some inoperative species as long as their number is not significant and force one into undue experimentation in order to practice the invention.
3. There is great diversity of the species deemed enabled by the Examiner.
4. The Examiner has provided no evidence to teach or suggest that the immunomodulatory effect observed from one bacterial species would not be expected from other species as well.

Applicant's arguments have been fully considered and deemed non-persuasive.

With regard to Point 1, Applicant's statement is correct however, given that a vast majority of bacterial species cannot be grown in the laboratory, screening them for the ability to produce immune modulating SRFs can hardly be deemed routine.

With regard to Point 2, given the diversity among bacterial species even within a given genus, it is deemed, in absence of evidence to the contrary, the number of inoperable species would indeed be significant.

With regard to Point 4, the art is silent with regard to any stress induced "molecule" (or any other molecule) that is produced by all (or even a majority of) bacterial species. Moreover, given that the "immunomodulator" present in the 10kDa fraction is not identified, the skilled artisan would have no idea what species (other than those disclosed in the specification) would be capable of producing the recited SRFs.

As outlined previously, enablement is considered in view of the Wands factors (MPEP 2164.01(A)). These include: nature of the invention, breadth of the claims, guidance of the specification, the existence of working examples, state of the art, predictability of the art and the amount of experimentation necessary.

In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) states, “The amount of guidance or direction needed to enable the invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art.” “The “amount of guidance or direction” refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling” (MPEP 2164.03). The MPEP further states that physiological activity can be

considered inherently unpredictable. Thus, Applicant assumes a certain burden in establishing that inventions involving physiological activity are enabled. All of the Wands factors have been considered with regard to the instant claims, with the most relevant factors discussed below.

Nature of the invention: The practice of this invention requires the use of bacteria that release certain low molecular weight stress release factors (SRFs) after exposure to sequential periods of stress and wherein said SRFs are capable of modulating the immune system of the animal when administered to said animal.

Breadth of the claims: The claims are extremely broad as they encompass all bacterial species.

Guidance of the specification/The existence of working examples: To use the instant invention the skilled artisan must know which bacterial species are capable of producing SRFs (in response to the recited stresses) that are capable of modulating the immune system upon its administration to an animal. The specification discloses that only 13 different species of animal-associated bacteria were found to “release products when stressed” (see page 4). The specification further discloses that the distribution of polymer:oligomer:monomer is not equal among the species (see page 4). Finally, the only bacterial species that were shown to release A254 absorbing compounds were set forth in Table 1 (see Example 1 on pages 16-17). Finally, of those bacterial strains set forth in Table 1 only *L. caseii* was shown to activate monocytes and the *Lactobacillus* species were demonstrated to increase monocyte survival.

State of the art: At the time of applicants' invention the art of using products produced by stressed bacteria (with a molecular weight less than 10 kDa) to modulate the immune system

of an animal was underdeveloped. While the use of heat shock proteins has been known in the art for years, the use of low molecular weight products is limited (see De Vuyst et al. (Microbiology, Vol. 142, 1996, pages 817-827, of record).

Predictability of the art and the amount of experimentation necessary: People of skill in the art require evidence that a benefit can be derived by the therapeutic application of a given substance; however, a survey of the relevant art does not indicate that substances such as those claimed provide such benefit. The instant specification fails to provide significant direction on which bacteria, other than those set forth in Table 1, are capable of eliciting a modulated immune response when administered to an animal. Moreover, the specification is silent as to which “product” within the <10kDa fraction is responsible for said modulation. Finally, as the response of individual species of bacteria to various stressors is quite variable, and the “identity” of the immunomodulatory unknown, the efficacy of a given <10kDa fraction from a given stressed bacteria has to be determined empirically. Given the enormous number bacterial species encompassed by the claims and the lack of guidance regarding the identity of the immunomodulatory, this constitutes undue experimentation.

Conclusion

No claim is allowed.

Claim 7 is objected to for being dependent on a rejected claim.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT A. ZEMAN whose telephone number is (571)272-0866. The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on (571) 272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Robert A. Zeman/
Primary Examiner, Art Unit 1645
August 18, 2008

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		09883550
	Filing Date		2001-06-18
	First Named Inventor		MARSHALL, William E.
	Art Unit		1645
	Examiner Name		ZEMAN, R.
	Attorney Docket Number		P01936US05

U.S.PATENTS						Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						
If you wish to add additional U.S. Patent citation information please click the Add button.						Add	
U.S.PATENT APPLICATION PUBLICATIONS						Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add	
FOREIGN PATENT DOCUMENTS						Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1						T ⁵
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add	
NON-PATENT LITERATURE DOCUMENTS						Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	09883550
	Filing Date	2001-06-18
	First Named Inventor	MARSHALL, William E.
	Art Unit	1645
	Examiner Name	ZEMAN, R.
	Attorney Docket Number	P01936US05

/RAZ/	1	PRESCOTT, L. et al., "Microbiology", 4th ed., WCB/McGraw-Hill 1999 (pp. 412, 413, 476, 478, 496 and 501). <input type="checkbox"/>
/RAZ/	2	GARRITY et al., "Taxonomic Outline of the Prokaryotes Bergey's Manual of Systematic Bacteriology, second ed., release 5.0, May 2004 (pp 1, 114-122, 181, 186-200, 298, and 299). <input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE


Examiner Signature	/Robert Zeman/	Date Considered	08/18/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

U.S. POSTAGE



Alexandria, VA 22313-1450
If Undeliverable Return in Ten Days

OFFICIAL BUSINESS
PENALTY FOR PRIVATE USE, \$300

AN EQUAL OPPORTUNITY EMPLOYER

MAILED FROM ZIP CODE 22314

\$ 01.170

00042-44935 ALC 22 2008

STAMPS USED

